Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash from Financing Activities (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Cash from Financing Activities for 16 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 111.66% year-over-year to $14.8 million; the TTM value through Dec 2025 reached $70.7 million, up 149.32%, while the annual FY2025 figure was $70.7 million, 149.32% up from the prior year.
  • Cash from Financing Activities hit $14.8 million in Q4 2025 for Sangamo Therapeutics, down from $19.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $43.8 million in Q3 2022 and bottomed at -$1.6 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $11.6 million, with a median of $8.1 million recorded in 2023.
  • Year-over-year, Cash from Financing Activities tumbled 110.29% in 2022 and then surged 9560.1% in 2025.
  • Sangamo Therapeutics' Cash from Financing Activities stood at $2.1 million in 2021, then soared by 824.95% to $19.5 million in 2022, then crashed by 99.15% to $167000.0 in 2023, then surged by 4086.23% to $7.0 million in 2024, then soared by 111.66% to $14.8 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $14.8 million, $19.2 million, and $28.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.